drugset
drugset / Trial / NCT06302426

Trial of INI-4001 in Patients With Advanced Solid Tumours

NCT06302426 ↗

Phase 1 Recruiting 50 enrolled Inimmune Corporation Avance Clinical Pty Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.

Timeline

Start
2024-07-01
Primary completion
2026-10-30
Completion
2027-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject INI-4001 Small molecule — Intravenous
Background Atezolizumab Monoclonal antibody — —
Background Avelumab Monoclonal antibody — —
Background Cemiplimab Monoclonal antibody — —
Background Durvalumab Monoclonal antibody — —
Background Nivolumab Monoclonal antibody — —
Background Pembrolizumab Monoclonal antibody — —

Indications

neoplasm